We can’t show the full text here under this license. Use the link below to read it at the source.
Long‐term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post‐hoc analysis of SURPASS ‐4
Long-term effectiveness and safety of tirzepatide in people with type 2 diabetes not well controlled by metformin or sulfonylurea
AI simplified
Abstract
1,500 participants treated with tirzepatide showed a greater mean reduction in HbA1c levels over 104 weeks compared to those on insulin glargine.
- At Week 104, tirzepatide 5 mg, 10 mg, and 15 mg resulted in mean HbA1c reductions of -2.3%, -2.5%, and -2.6%, respectively.
- The insulin glargine group had a mean HbA1c reduction of -1.0%.
- Participants in the tirzepatide groups lost more weight, with reductions of -7.6 kg, -10.0 kg, and -11.4 kg compared to 2.1 kg in the insulin glargine group.
- A higher proportion of tirzepatide participants achieved HbA1c levels below 7.0% compared to those on insulin glargine.
- The incidence of hypoglycaemia was lower in the tirzepatide groups, with gastrointestinal adverse events primarily mild or moderate.
AI simplified
Key numbers
-2.6%
Reduction
Mean reduction in for tirzepatide 15 mg group vs. insulin glargine.
-11.4 kg
Body Weight Change
Mean weight reduction for tirzepatide 15 mg group vs. insulin glargine.
p < 0.001
Participants Achieving <7.0%
Comparison of proportions achieving <7.0% between treatment groups.